AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025 28-08-2025, 18:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai 18-09-2024, 22:07

Fluence Stands by its Work on the Diablo Plant, and Will Vigorously Pursue the Payments it is Owed for its Work and Dispute the Allegations in the Counterclaim Filed by the Operator of the Plant 21-12-2023, 04:25